Inisiasi Fixed Ratio Combination (FRC) Insulin Glargine/Lixisenatide untuk Orang Dewasa dengan Diabetes Melitus Tipe 2
DOI:
https://doi.org/10.55175/cdk.v50i12.1014Keywords:
Iglarlixi, Fixed Ratio Combination, Type 2 diabetes mellitus, hyperglycaemiaAbstract
Hyperglycaemia is a medical condition of increased blood glucose levels, which is characteristic of several diseases, especially diabetes mellitus. Diabetes mellitus is currently a global threat to health. A fixed-ratio combination a insulin glargine and lixisenatide (iGlarLixi) is a product
containing glargine insulin (a long-acting insulin) and lixisenatide (a glucagon-like peptide-1 receptor agonist) in one single injection. Fixed ratio combination offers many clinical benefits for adults with type 2 diabetes mellitus.
Downloads
References
PERKENI. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. PB PERKENI; 2021
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017 Estimates of Diabetes and Its Burden in the United States Background [Internet]. 2020. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med. 2021;384(23):2219–28.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753–86.
Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood EG, Hollander P, et al. Impact of simultaneous versus sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists on HbA1c in type 2 diabetes: A retrospective observational study. Diabetes Ther. 2020;11(4):995–1005.
American Diabetes Association. Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes 2020;38(1):10–38.
American Association of Clinical Endocrinology. 2023 AACE consensus statement: Comprehensive type 2 diabetes management algorithm [Internet]. [cited 2023 May 22]. Available from: https://pro.aace.com/clinical-guidance/2023-aace-consensus-statement-comprehensive-type-2-diabetes-management-algorithm?gclid=CjwKCAjwpayjBhAnEiwA-7ena6YcTglvwnpfkBrndI-4EwfS75R2MJUdWOVMCoqTN4U669mhQjePwRoCZ00QAvD_BwE
Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Advances in Therapy. 2019;36(2):265–77.
Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes, Obesity and Metabolism. 2014;17(2):145–51.
Kramer W. Exp Clin Endocrinol Diabetes. 1999;107(suppl 2):S52. http://dx.doi.org/10.1055/s-0029-1212151
Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technol Therapeut. 2011 Jun;13(S1):33-42.
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.
Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides 2010 Sep 24;164(2-3):58–64.
Annex I summary of product characteristics [Internet]. [cited 2023 May 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/suliqua-epar-product-information_en.pdf
Haluzik M, Flekač M, Lengyel C, Zoltán Taybani, Cristian Guja, Mihai BM, et al. Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide: A Central/Eastern European Perspective. Diabetes Ther. 2020 Apr;11(4):1029-43.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of lixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The lixiLan-O randomized trial. Diabetes Care
;39(11):2026–35.
PERKENI. Pedoman pemantauan glukosa darah mandiri 2021. PB PERKENI, editor. PB PERKENI; 2021. 22-10-21-Website-Pedoman-Pemantauan-Glukosa-Darah-Mandiri-Ebook.pdf (pbperkeni.or.id)
Sanofi-Aventis Deutschland GmbH. Lantus® (insulin glargine 100 units/mL) Summary of Product Characteristics, 2017. https://pdf.hres.ca › dpd_pm
Highlights of Prescribing Information Soliqua. BPOM, 2021
Leaflet Informasi untuk Pengguna Soliqua, BPOM 2019
PERKENI. Pedoman petunjuk praktis terapi insulin pada pasien diabetes melitus 2021. PB PERKENI [Internet]. 2021. Available from: https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-_-Website-Pedoman-Petunjuk-Praktis-Terapi-Insulin-Pada-Pasien-Diabetes-Melitus-Ebook.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Muhammad Ikhsan Mokoagow
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
